newswire.com /1 month ago

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia followi...

Read source
biopharmadive.com /3 weeks ago

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

Read source
medcitynews.com /3 weeks ago

Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designe...

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
qchron.com /3 weeks ago

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U...

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint.

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Onswik for Adults with Type 2 Diabetes ]]>

Read source
drugs.com /2 weeks ago

GLP-1 Drugs Can Help Reverse Prediabetes, Researchers Report

WEDNESDAY, Nov. 4, 2026 — Cutting-edge weight-loss drugs like Ozempic and Zepbound are helping people reverse prediabetes and avoid heart attack and stroke more effectively than st...

Read source
bioengineer.org /1 month ago

Combination therapy improves heart failure measures in retrospective Chinese cohort

A retrospective study of 150 Chinese heart-failure patients found that adding dapagliflozin to sacubitril-valsartan was associated with better cardiac-function measures, lower biom...

Read source
pharmexec.com /1 month ago

<![CDATA[EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe]]>

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.